Current Headlines

  1. PBT2 Recommended For Orphan Designation In Europe
    4/27/2015

    Prana Biotechnology is pleased to announce the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC)

  2. PharmaEngine Announces Merrimack Completed MM-398 (PEP02) New Drug Application Submission To U.S. FDA
    4/27/2015

    PharmaEngine, Inc. recently announced that its licensing partner, Merrimack Pharmaceuticals, Inc. has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection) to the U.S

  3. Celgene To Acquire Quanticel Pharmaceuticals
    4/27/2015

    Celgene Corporation and Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery, recently announced a definitive share purchase agreement under which Celgene Corporation will acquire Quanticel

  4. Lilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval
    4/24/2015

    Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

  5. FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna’s Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
    4/23/2015

    Dicerna Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, recently announced that the U.S

  6. Mesothelioma Immunotherapy Vaccine Receives Orphan Drug Designation From FDA, Baron & Budd Reports
    4/23/2015

    The mesothelioma law firm of Baron & Budd reports the U.S

  7. PPD Honored For Patient-Centric Communications On Clinical Research
    4/23/2015

    Pharmaceutical Product Development, LLC (PPD) recently announced it has won recognition for a patient-centered communications campaign demonstrating the company’s commitment to helping biopharmaceutical clients deliver life-changing medical treatments

  8. Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics
    4/21/2015

    Astellas Pharma Inc. and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, recently announced an exclusive research and development collaboration

  9. Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer
    4/21/2015

    Pfizer Inc. announced recently that XALKORI (crizotinib) received Breakthrough Therapy designation by the U.S

  10. Investigational Brain Cancer Vaccine Produces Strong Immunological Response
    4/21/2015

    A first-of-its kind cancer vaccine, SurVaxM, has demonstrated safety and tolerability in patients with recurrent or progressive malignant brain tumors, according to results of a phase I study conducted by Roswell Park Cancer Institute (RPCI) researchers.

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.